WO2014164067A1 - Constructions de liaison à l'antigène se liant à cd30 - Google Patents

Constructions de liaison à l'antigène se liant à cd30 Download PDF

Info

Publication number
WO2014164067A1
WO2014164067A1 PCT/US2014/020318 US2014020318W WO2014164067A1 WO 2014164067 A1 WO2014164067 A1 WO 2014164067A1 US 2014020318 W US2014020318 W US 2014020318W WO 2014164067 A1 WO2014164067 A1 WO 2014164067A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen binding
binding construct
seq
diabody
cys
Prior art date
Application number
PCT/US2014/020318
Other languages
English (en)
Inventor
David T. HO
Tove Olafsen
Giti AGAHI
Jean Gudas
Original Assignee
Imaginab, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imaginab, Inc. filed Critical Imaginab, Inc.
Publication of WO2014164067A1 publication Critical patent/WO2014164067A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Abstract

L'invention concerne des constructions de liaison à l'antigène qui se lient à CD30, par exemple des anticorps, comprenant des fragments d'anticorps (tels que scFv, des mini-anticorps, et cys-diabodies) qui se lient à CD30. L'invention concerne aussi des procédés d'utilisation.
PCT/US2014/020318 2013-03-12 2014-03-04 Constructions de liaison à l'antigène se liant à cd30 WO2014164067A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361777832P 2013-03-12 2013-03-12
US61/777,832 2013-03-12
US201361780014P 2013-03-13 2013-03-13
US61/780,014 2013-03-13

Publications (1)

Publication Number Publication Date
WO2014164067A1 true WO2014164067A1 (fr) 2014-10-09

Family

ID=51658816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/020318 WO2014164067A1 (fr) 2013-03-12 2014-03-04 Constructions de liaison à l'antigène se liant à cd30

Country Status (1)

Country Link
WO (1) WO2014164067A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108610420A (zh) * 2016-12-13 2018-10-02 科济生物医药（上海）有限公司 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
WO2022074206A1 (fr) 2020-10-08 2022-04-14 Affimed Gmbh Lieurs trispécifiques
WO2023007023A1 (fr) 2021-07-30 2023-02-02 Affimed Gmbh Corps duplex
WO2023078968A1 (fr) 2021-11-03 2023-05-11 Affimed Gmbh Liants de cd16a bispécifiques

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20100239571A1 (en) * 2006-08-25 2010-09-23 Seattle Genetics, Inc. CD30 Binding Agents and Uses Thereof
US20110268656A1 (en) * 2009-12-02 2011-11-03 David Ho J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US20120195900A1 (en) * 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20100239571A1 (en) * 2006-08-25 2010-09-23 Seattle Genetics, Inc. CD30 Binding Agents and Uses Thereof
US20110268656A1 (en) * 2009-12-02 2011-11-03 David Ho J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US20120195900A1 (en) * 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108610420A (zh) * 2016-12-13 2018-10-02 科济生物医药（上海）有限公司 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
JP2020503015A (ja) * 2016-12-13 2020-01-30 カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 抗ｃｄ１９のヒト化抗体及びｃｄ１９を標的とする免疫エフェクター細胞
EP3556772A4 (fr) * 2016-12-13 2020-09-09 Carsgen Therapeutics Ltd Anticorps humanisé anti-cd19 et cellule effectrice immunitaire ciblant cd19
CN108610420B (zh) * 2016-12-13 2023-09-26 科济生物医药（上海）有限公司 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
WO2022074206A1 (fr) 2020-10-08 2022-04-14 Affimed Gmbh Lieurs trispécifiques
WO2023007023A1 (fr) 2021-07-30 2023-02-02 Affimed Gmbh Corps duplex
WO2023078968A1 (fr) 2021-11-03 2023-05-11 Affimed Gmbh Liants de cd16a bispécifiques

Similar Documents

Publication Publication Date Title
US10882909B2 (en) Antigen binding constructs to CD3
US20200140550A1 (en) Antigen binding constructs to cd8
US20220089730A1 (en) Antigen binding constructs to target molecules
US20210371527A1 (en) Antigen binding constructs to cd4
WO2014158821A1 (fr) Constructions de liaison d'antigène à cd70
WO2014137931A1 (fr) Constructions de liaison à un antigène se liant à 5t4
WO2014164067A1 (fr) Constructions de liaison à l'antigène se liant à cd30

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14778297

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14778297

Country of ref document: EP

Kind code of ref document: A1